Choongwae Announces KFDA Approval of Extended Indications for Provigil

Published: 2005-03-31 06:58:00

Updated: 2005-03-31 06:58:00

Choongwae Pharmaceutical announced that the Korea Food and Drug Administration (KFDA) has approved additional therapeutic indications for Provigil (active ingredient: modafinil), which is currently prescribed to over 30,000 domestic patients with excessive sleepiness associated with narcolepsy.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK